glp-1 gip therapy effectiveness weight loss Rx Trends: Real-World Data on GLP-1s for Glucagon-like peptide-1 receptor: mechanisms and
Description
I've been prescribing GLP-1 medications since 2015, starting with exenatide and moving through every generation of these therapies
However, treatment discontinuation due to adverse events occurred in 24.6% and 3.9% of participants, respectively, mainly due to gastrointestinal adverse events
GIP but not GLP-1 facilitates fat deposition
Genetics of gallstone disease and their clinical significance: a narrative review
